Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-Positive 'Triple Receptor-Negative' Breast Cancer
This study is currently recruiting participants.
Study NCT00739063.   Last updated on February 18, 2009.
Information provided by M.D. Anderson Cancer Center
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
Additional conditions recognized in this trial
Breast Neoplasms
More general conditions related to this trial
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases
Interventions listed in this trial
Tarceva
Additional drug interventions recognized in this trial
Erlotinib
More general drug interventions related to this trial
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Sponsors listed in this trial
M.D. Anderson Cancer Center
OSI Pharmaceuticals


U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services